A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
← catalyst calendarNCT07391657 · readout in 665 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
508estimated
Sites
142
Countries
Australia, Brazil, Canada +12
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-02-23 | actual | When the study began enrolling |
| Primary completion | 2028-06-14 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-07-29 | estimated | The whole study's end, after follow-up |
| First posted | 2026-02-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Relapsed Refractory Multiple Myeloma
Interventions
- Biological: AZD0120
- Drug: Daratumumab — also filed as Darzalex
- Drug: Carfilzomib — also filed as Kyprolis
- Drug: Dexamethasone
- Drug: Bortezomib — also filed as Velcade
- Drug: Pomalidomide — also filed as Pomalyst and Imnovid
Primary outcomes
what the primary-completion date above is the date OFTo demonstrate the superiority of AZD0120 relative to standard therapy (DKd, DPd, PVd, or Kd) by assessment of PFS in participants with RRMM.
measured 3 years
To demonstrate the superiority of AZD0120 relative to standard therapy (DKd, DPd, PVd, or Kd) by assessment of MRD negativity rate at 9 months in participants with RRMM.
measured 2 years
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed